⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8377751 | 0.83 | — | — | |
| SCHEMBL31411206 | 0.79 | PTGS1 (0.39) | — | |
| SCHEMBL31411207 | 0.79 | PTGS1 (0.39) | — | |
| SCHEMBL12518176 | 0.76 | ALDH1A1 (0.48) | — | |
| SCHEMBL25468801 | 0.74 | — | — | |
| SCHEMBL12817567 | 0.74 | — | — | |
| SCHEMBL13757902 | 0.74 | — | — | |
| SCHEMBL16288191 | 0.74 | — | — | |
| SCHEMBL14748107 | 0.74 | — | — | |
| SCHEMBL16287957 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9765065-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9591935-B2 | Therapeutic substituted cyclopentanes | ALLERGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130231322-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-7700627-B2 | Therapeutic substituted lactams | ALLERGAN, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090270387-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090215740-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | ALLERGAN, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-7576112-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2009055289-A2 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090099249-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| US-7507817-B2 | Glaucome therapy; vision defects | ALLERGAN, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080167311-A1 | Prostaglandin Prodrugs | ALLERGAN, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080119539-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080027108-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. | 2008-01-31 | — | — | US | disclosed |